For the last 30 days, iBio’s stock was mainly declining. Yesterday, the stock reached $1.33 point. However, today after great news it is starting to surge. In pre-market it is expected to be $1.48, which results in a good 11% boost. The company has taken another major step towards increasing the speed and performance of its patented FastPharming Protein Expression System®, a plant-based protein expression system, announcing today the addition of three cancer targets to its therapeutic candidate portfolio.
Accordingly, iBio entered into a research services agreement with FairJourney Biologics S.A. (“FairJourney”), a leader in antibody optimization. Under the agreement, iBio will have access to new imaging technologies and proprietary antibody libraries.